Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: Avacta Group Plc

Capitalization 30Cr 40Cr 35Cr 32Cr 55Cr 3.73TCr 57Cr 373.04Cr 148.7Cr 1.78TCr 151.79Cr 148.59Cr 6.42TCr P/E ratio 2025 *
-10x
P/E ratio 2026 * -11.7x
Enterprise value 30Cr 40Cr 34Cr 31Cr 54Cr 3.66TCr 56Cr 366.33Cr 146.02Cr 1.75TCr 149.05Cr 145.92Cr 6.31TCr EV / Sales 2025 *
47.4x
EV / Sales 2026 * -
Free-Float
66.47%
Yield 2025 *
-
Yield 2026 * -

Last Transcript: Avacta Group Plc

1 day+0.73%
1 week+0.73%
Current month+2.22%
1 month+15.97%
3 months-10.39%
6 months+25.45%
Current year+18.97%
1 week 61
Extreme 61
72
1 month 53
Extreme 53
75
Current year 48
Extreme 48
75
1 year 26
Extreme 26
84
3 years 26
Extreme 26
166.98
5 years 26
Extreme 26
291.8
10 years 13
Extreme 13
291.8
Manager TitleAgeSince
Chief Executive Officer 56 01/04/2024
Director of Finance/CFO 51 22/01/2025
Chief Tech/Sci/R&D Officer - 09/02/2026
Director TitleAgeSince
Director/Board Member 58 28/05/2025
Director/Board Member 60 03/02/2020
Director/Board Member 71 17/08/2021
Change 5d. change 1-year change 3-years change Capi.($)
+0.73%+0.73%+70.37%-49.82% 40Cr
-1.03%-1.53%+20.96%+95.67% 4.48TCr
-1.34%+0.95%+50.72%+15.79% 4.03TCr
-3.09%-6.99%+89.15%+675.31% 3TCr
+8.28%-12.49%-7.67%-28.72% 2.18TCr
-2.60%-0.85%+48.90%-30.00% 1.91TCr
-1.84%-2.06%+27.10%-28.71% 1.67TCr
-2.79%+9.61%+56.15%+181.97% 1.35TCr
-1.53%+4.55%-13.08%+979.19% 1.25TCr
-3.99%+5.46%+66.38% - 1.21TCr
Average -0.92%+2.23%+40.90%+201.19% 2.11TCr
Weighted average by Cap. -0.94%+0.07%+39.33%+191.69%

Financials

2025 *2026 *
Net sales 62.5L 83.77L 72.39L 65.35L 1.14Cr 77Cr 1.17Cr 7.73Cr 3.08Cr 37Cr 3.14Cr 3.08Cr 133.05Cr -
Net income -3.51Cr -4.71Cr -4.07Cr -3.67Cr -6.4Cr -434.15Cr -6.58Cr -43Cr -17Cr -207.59Cr -18Cr -17Cr -747.72Cr -3.15Cr -4.23Cr -3.65Cr -3.3Cr -5.75Cr -389.96Cr -5.91Cr -39Cr -16Cr -186.46Cr -16Cr -16Cr -671.61Cr
Net Debt -54.32L -72.8L -62.91L -56.8L -99.01L -67Cr -1.02Cr -6.71Cr -2.68Cr -32Cr -2.73Cr -2.67Cr -115.63Cr 1.68Cr 2.25Cr 1.95Cr 1.76Cr 3.06Cr 207.69Cr 3.15Cr 21Cr 8.28Cr 99Cr 8.45Cr 8.27Cr 357.7Cr
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.
Employees
151
Date Price Change Volume
11/26/11 69.00 p +0.73% 12,57,338
10/26/10 68.50 p +5.38% 11,11,928
09/26/09 65.00 p -3.70% 20,05,474
06/26/06 67.50 p -4.93% 18,15,111
05/26/05 71.00 p +3.65% 23,82,295
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.6900GBP
Average target price
0.8000GBP
Spread / Average Target
+15.94%

Annual profits - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW